NASDAQ · Biotechnology

Trevi Therapeutics, Inc. (TRVI) Stock

$12.83 -2.40% NASDAQ: TRVI Healthcare

Valuation

MetricValue
Price$12.83
Market Cap$1.82B
P/E Ratio-43.32
P/B Ratio7.13
P/S Ratio0.00
EPS (TTM)$-0.32
52-Week High$20.22
52-Week Low$8.99
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-23.59%
ROA-15.46%
ROCE-18.51%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio24.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-32.0M$-30.0M$-34.0M$-52.0M$-49.0M
Net Profit$-34.0M$-29.0M$-29.0M$-48.0M$-43.0M
EPS$-1.49$-0.45$-0.29$-0.47$-0.29
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$38.0M$123.0M$89.0M$111.0M$193.0M
Total Liabilities$21.0M$16.0M$7.0M$11.0M$10.0M
Cash$37.0M$13.0M$32.0M$34.0M$19.0M
Borrowings$15.0M$9.0M$1.0M$1.0M$1.0M

Latest News

BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target MT Newswires · Jul 21, 2026 B. Riley Adjusts Trevi Therapeutics Price Target to $31 From $21, Maintains Buy Rating MT Newswires · Jul 20, 2026 Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market Insider Monkey · Jul 18, 2026 Trevi Therapeutics Announces Upcoming June and July Event Schedule GlobeNewswire · Jun 17, 2026 Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. Motley Fool · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-29.0M$-28.0M$-32.0M$-38.0M$-42.0M
Investing Cash Flow$0$-108.0M$59.0M$-22.0M$-94.0M
Financing Cash Flow$0$12.0M$0$0$1.0M
Net Cash Flow$-8.0M$-24.0M$20.0M$2.0M$-15.0M
Free Cash Flow$-29.0M$-28.0M$-32.0M$-38.0M$-42.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-2.27
EV / EBITDA-39.63
FCF Yield-1.90%
Quick Ratio37.28
Interest Coverage0.00
Return 1Y148.00%
Return 3Y638.72%
Return 5Y776.77%

Ownership

Insiders Held0.63%
Institutions Held99.26%
Institutions Float Held99.89%
Institutional HolderSharesReport Date
NEA Management Company, LLC13,222,2282026-03-31
Blackrock Inc.10,240,1862026-03-31
Frazier Life Sciences Management, L.P. 9,939,5472026-03-31
FMR, LLC8,038,0612026-03-31
Wellington Management Group, LLP5,189,0882026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACADACADIA Pharmaceuticals Inc. $19.58 -0.36% 8.87 $3.35B 0.00%
LQDALiquidia Corporation $28.02 +5.02% 19.28 $2.49B 0.00%
LXRXLexicon Pharmaceuticals, Inc. $1.76 +0.00% -12.10 $781.78M 0.00%
RAPPRapport Therapeutics, Inc. $29.85 -3.27% -10.38 $1.43B 0.00%
TBPH $17.03 +0.00% 16.05 $882.64M 0.00%

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. (TRVI) stock trades at $12.83 with a market capitalization of $1.82B. The stock is valued at a price-to-earnings (P/E) ratio of -43.32, price-to-book of 7.13, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.99 and $20.22, and currently trades 36.5% below its 52-week high.

On profitability, Trevi Therapeutics, Inc. generates a return on equity (ROE) of -23.59%, return on capital employed of -18.51%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1162.55 -0.60% JNJ Johnson & Johnson $257.43 +0.37% ABBV AbbVie Inc. $274.33 +0.70% MRK Merck & Company, Inc. Common Stock (new) $143.09 +0.50% UNH UnitedHealth Group Incorporated Common Stock (DE) $384.13 +3.55% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $656.66 +0.72% AMGN Amgen Inc. $406.05 -0.34% GILD Gilead Sciences, Inc. $147.20 +0.07% ABT Abbott Laboratories $98.92 +0.44% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides